Clinical trials: Obesity or Overweight
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in…
- Trial name
- NCT07665879
- Testing
- Eloralintide
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18…
- Trial name
- GZR18-BWM-303 (NCT07292441)
- Testing
- GZR18 injection
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Genetic Forms of Extreme Obesity
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
A voluntary prospective study that will allow registration and follow-up of individuals with MC4R pathway genetic obesity.
- Trial name
- NCT03479437
- Where
- 2 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients
The primary objective of this study is to assess the effect of rimonabant on the energy intake (kcal/day/meal) from ad-libitum high-fat dinner (primary endpoint), pre- and post-ingestive responses, and the hedonic evaluation of…
- Trial name
- REBA (NCT00481923)
- Testing
- rimonabant (SR141716)
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Sanofi
Insulin Sensitivity, Overweight or Obesity
Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human
Objective 1: Characterize indices of systemic inflammation and gut microbiota composition and function after chronic (12 weeks) intake of pulses compared to control diet in human OW/OB-IR participants.
- Conditions
- Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
- Trial name
- PS (NCT04267705)
- Testing
- Control, Black bean, Chickpea
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Overweight, Obesity
A Study of LY3305677 in Participants With Obesity Or Overweight
The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight.
- Trial name
- NCT05623839
- Testing
- LY3305677
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like birth control tablets, and emptying of the stomach in women not able to become pregnant living with…
- Trial name
- NCT07710729
- Testing
- UBT251, Oral contraceptive, Acetaminophen
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight.
- Trial name
- NCT07808073
- Testing
- LY4329090
- Where
- 3 sites in United States, Singapore
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Weight Loss
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- NCT07104383
- Testing
- VK2735
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 1,100 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity
A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days.
- Trial name
- NCT04447261
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity.
- Trial name
- NCT07557953
- Testing
- Cagrilintide
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Overweight or Obese
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
- Trial name
- NCT07036601
- Testing
- THDBH120 injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus Combined With Overweight or Obesity
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study designed to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of multiple oral doses of TQF3250…
- Trial name
- NCT07747857
- Testing
- TQF3250 capsules
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sleep Apnea, Obstructive, Obesity
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight.
- Conditions
- Sleep Apnea, Obstructive, Obesity, Overweight
- Trial name
- ENLIGHTEN-3 (NCT07369011)
- Testing
- Eloralintide
- Where
- 115 sites in United States, Australia and 9 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin
- Trial name
- NCT06064006
- Testing
- NNC0487-0111
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novo Nordisk A/S
Obesity, Dyslipidemias
European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia
Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with…
- Trial name
- ETERNAL (NCT00412698)
- Testing
- rimonabant
- Where
- 15 sites in Czechia, Finland and 13 more
- Volunteers
- 645 people
- Sponsor
- Sanofi
Overweight or Obesity, Healthy
Anti-inflammatory Effect and Associated Mechanisms of Mango Consumption
The primary objective of this project is to provide new knowledge through a comprehensive set of analyses that investigate the complex interplay between regular mango intake, gut microbial structure/ function, mechanisms of…
- Trial name
- MG2 (NCT04726293)
- Testing
- Mango, Control
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology